Rhythm's Imcivree scores 'transformative' FDA approval in brain damage-related obesity

20th March 2026 Uncategorised 0

The new FDA nod makes Rhythm Pharma’s Imcivree the first approved drug for acquired hypothalamic obesity and brings the drug’s first expansion beyond rare genetic-driven obesities.

More: Rhythm's Imcivree scores 'transformative' FDA approval in brain damage-related obesity
Source: fierce